Anastrozole is a non-steroidal aromatase inhibitor that suppresses the enzyme responsible for converting androgens into estrogens. This reduction in estrogen availability forms the basis of its therapeutic action.

Arimidex is primarily associated with hormonal treatment of estrogen-receptor-positive breast cancer, particularly in postmenopausal women. Treatment selection depends on the patient’s diagnosis, menopausal status, previous therapy, and overall clinical circumstances.

The supplied product specifies a 1mg strength. Because reduced estrogen can affect bone density, joints, and cardiovascular risk factors, long-term treatment may require appropriate clinical monitoring.